GSK429286A (RHO-15) is a specific inhibitor of ROCK1/2 (IC50: 14/63 nM).

ROCK2:63 nM, ROCK1:14 nM

GSK429286A（3-30 mg/kg,p.o.）剂量依赖性显著降低自发性高血压大鼠的平均动脉压, GSK429286A（30 mg/kg）处理约2 h后,最大降低50 mmHg.在雄性Sprague-Dawley大鼠体内,GSK429286A的口服生物利用度为61%.

GSK429286A（1 μM）可使ROCK2活性降低20倍,该浓度下仅有MSK1的活性降低了约5倍。与ROCK常用抑制剂Y-27632相比,GSK429286A是选择性更高的ROCK2抑制剂,即使30 μM对LRRK2也无明显抑制,IC50比对ROCK2的高500倍。与GSK269962A相同,在HEK-293细胞中,GSK429286A（10 μM）可消除基底或G14V-Rho突变体诱导的MYPT Thr850上的磷酸化作用,效果与H-1152和Y-27632相似,与ROCK介导的磷酸化一致,G14V-Rho是否存在,GSK429286A均不影响ERM蛋白磷酸化。GSK429286A对RSK（IC50：0.78 μM）和p70S6K（IC50：1.94 μM）也有轻度抑制。GSK429286A对大鼠主动脉环扩张有显著抑制（IC50：190 nM）。

Binding affinity assays: TR-FRET-binding affinity assays are performed for BCL-2, BCL-XL, and MCL-1 in 4.52?mM monobasic potassium phosphate, 15.48?mM dibasic potassium phosphate, 1?mM sodium EDTA, 0.05% Pluronic F-68 detergent, 50?mM sodium chloride, and 1?mM DTT (pH 7.5). For MCL-1 assays, GST-tagged MCL-1 (1?nM) is mixed with 100?nM f-Bak, 1?nM Tb-labeled anti-GST antibody, and compound at room temperature (RT) for 60?min. Fluorescence is measured on an Envision plate reader using a 340/35?nm excitation filter and 520/525 (f-Bak) and 495/510?nm (Tb-labeled anti-GST antibody) emission filters.